Remdesivir-Related Cardiac Adverse Effects in COVID-19 Patients: A Case-Control Study
Drug Research · 01.07.2024 · 74 (06) · 290-295
DOI: 10.1055/a-2332-3253 ↗Kurz gefasst
Fall-Kontroll-Studie in der Zeitschrift Drug Research, erschienen am 01.07.2024. Verfasst von Fatemah Abedipour und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Disease, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran. Hauptthemen laut MEDLINE: Alanine, Adenosine Monophosphate, COVID-19 Drug Treatment, Antiviral Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 37 Literaturangaben.
Abstract (Originalsprache)
Background
There have been reports of serious side effects of Remdesivir, including cardiovascular complications. The present study aimed to determine the adverse cardiovascular effects of Remdesivir and the factors affecting them in COVID-19 patients.
Methods
The patients were classified into two groups: those receiving Remdesivir without cardiac complications and those receiving Remdesivir with cardiovascular complications. After reviewing the patientʼs medical records, the relationship of some factors with the incidence of adverse cardiovascular effects was measured.
Results
Chi-square test showed that the distribution of complications in men was significantly higher than in women (P=0.001). The independent t-test revealed that the mean age in the group with complications was significantly higher than the group without complications (P=0.013). Fisherʼs exact test demonstrated a significant relationship between smoking and cardiovascular complications (P=0.05). According to the Mann-Whitney test, a significant difference was found in the mean changes of Bilirubin (P=0.02) and ALKP (P=0.01) before and after treatment in the groups with and without heart complications.
Conclusion
Our findings indicated that most of the COVID-19 patients suffered from sinus bradycardia, and the distribution of complications was more pronounced in men than in women. The mean age in the group with complications was higher than the group without complications. Smoking was found to be associated with the occurrence of cardiovascular complications and the mean changes of Bilirubin and ALKP before and after treatment were significantly different in the groups with and without cardiovascular complications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Infectious Disease, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran.
- Infectious Diseases and Tropical Medicine Research Center, Research Institute of Cellular and Molecular Sciences in Infectious Diseases, Zahedan University of Medical Sciences, Zahedan, Iran.
- Health Promotion Research Center, Zahedan University of Medical Sciences, Zahedan, Iran.
- Department of Cardiology, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran.
- Pharmacology Research Center, Zahedan University of Medical Sciences, Zahedan, Iran.
- Department of Pharmacology, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran.
ORCID-Profile: Asma Rashki
Zitieren
APA
Abedipour, F., Mirzaei, H. H., Ansari, H., Ehsanzadeh, N., Rashki, A., Vahedi, M. M., & Rashki, A. (2024). Remdesivir-Related Cardiac Adverse Effects in COVID-19 Patients: A Case-Control Study. Drug Research, 74(06), 290-295. https://doi.org/10.1055/a-2332-3253
Vancouver
Abedipour F, Mirzaei HH, Ansari H, Ehsanzadeh N, Rashki A, Vahedi MM, et al. Remdesivir-Related Cardiac Adverse Effects in COVID-19 Patients: A Case-Control Study. Drug Research. 2024;74(06):290-295. doi:10.1055/a-2332-3253
BibTeX
@article{Abedipour2024,
author = {Abedipour, Fatemah and Mirzaei, Hossein Hadavand and Ansari, Hossein and Ehsanzadeh, Neda and Rashki, Amin and Vahedi, Mohammad Mahdi and Rashki, Asma},
title = {Remdesivir-Related Cardiac Adverse Effects in COVID-19 Patients: A Case-Control Study},
journal = {Drug Research},
year = {2024},
volume = {74},
number = {06},
pages = {290--295},
doi = {10.1055/a-2332-3253}
}
EUVIMED